Savara (SVRA) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Program and regulatory update

• MOLBREEVI, a late-stage therapy for autoimmune PAP, has been resubmitted for FDA approval with Fujifilm as the new primary manufacturer after addressing prior manufacturing data issues.

• The resubmitted BLA is expected to be accepted soon, with priority review likely, targeting a PDUFA date in August.

• MAAs for Europe and the UK are on track for filing by the end of Q1, with plans to commercialize independently in those regions.

• The company is well-capitalized, with $264 million on the balance sheet and access to additional non-dilutive capital upon FDA approval.

Clinical data and endpoints

• Phase III results showed statistically significant improvement in DLco at 24 and 48 weeks, with robust secondary endpoint data (SGRQ and exercise tolerance).

• DLco is a validated, reproducible surrogate endpoint for autoimmune PAP, reflecting clinical impact and disease progression.

• SGRQ improvements met the minimal clinically important difference, supporting clinical benefit.

Commercial strategy and market opportunity

• Claims analysis identified about 5,500 diagnosed aPAP patients in the US; line of sight confirmed 1,000 patients, representing 20% of the market.

• The market is concentrated, with the top 500 accounts covering two-thirds of patients, enabling efficient launch targeting.

• Specialty pharmacy partner PANTHERx will support product distribution and patient access.

• Disease awareness campaigns and diagnostic testing (including a dry blood spot test) are expanding identification of undiagnosed patients.